The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE
Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/uniqure-loss-submission-form/?id=183651&from=4
CLASS PERIOD:
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the design of uniQure's Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License Application ("BLA") timeline to perform additional studies to supplement its BLA submission; and (3) as a result, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.
DEADLINE:
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of QURE during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is
WHY GROSS LAW FIRM?
CONTACT:
Email:
Phone: (646) 453-8903
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-april-13-2026-in-uniqure-lawsuit--qure-302692452.html
SOURCE